Nonalcoholic fatty liver disease and metabolic syndrome: A concise review

Romanian Journal of Morphology and Embryology

Volumn 49, Issue 1, 2008, Pages 13-20

  Streba, Letiţia Adela Maria ^a   Cârstea, Doina ^a   Mitrut P ^b   Vere, C C ^b   Dragomir, Nicoleta ^a   Streba, C T ^c  

^a 'Filantropia' University Hospital of Craiova   (Romania)

^b Emergency County Hospital of Craiova   (Romania)

^c UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Adiponectin; Insulin resistance; Metabolic syndrome; NAFLD; NASH

Indexed keywords

ADIPOSE TISSUE; CONCEPT FORMATION; FATTY LIVER; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PHYSIOLOGY; REVIEW;

ADIPOSE TISSUE; CONCEPT FORMATION; FATTY LIVER; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OXIDATIVE STRESS;

EID: 51449092910     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Neuschwander-Tetri B. A., Caldwell S. H., Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference, Hepatology, 2003, 37(5):1202-1219.
2. Adams L. A., Angulo P., Recent concepts in non-alcoholic fatty liver disease, Diabet Med, 2005, 22(9):1129-1133.
3. Farrell G. C., Chitturi S., Lau G. K., Sollano J. D.; Asia-Pacific Working Party on NAFLD, Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary, J Gastroenterol Hepatol, 2007, 22(6):775-777.
4. Angulo P., Nonalcoholic fatty liver disease, N Engl J Med, 2002, 346(16):1221-1231.
5. Farrell G. C., Larter C. Z., Nonalcoholic fatty liver disease: from steatosis to cirrhosis, Hepatology, 2006, 43(2 Suppl 1):S99-S112.
6. Ludwig J., Viggiano T. R., McGill D. B., Oh B. J., Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease, Mayo Clin Proc, 1980, 55(7):434-438.
7. Sheth S. G., Gordon F. D., Chopra S., Nonalcoholic steatohepatitis, Ann Intern Med, 1997, 126(2):137-145.
8. Clark J. M., Brancati F. L., Diehl A. M., The prevalence and etiology of elevated aminotransferase levels in the United States, Am J Gastroenterol, 2003, 98(5):960-967.
9. Daniel S., Ben-Menachem T., Vasudevan G., Ma C. K., Blumenkehl M., Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients, Am J Gastroenterol, 1999, 94(10):3010-3014.
10. Caldwell S. H., Oelsner D. H., Iezzoni J. C., Hespenheide E. E., Battle E. H., Driscoll C. J., Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease, Hepatology, 1999, 29(3):664-669.
11. García-Monzón C., Martín-Pérez E., Iacono O. L., Fernández-Bermejo M., Majano P. L., Apolinario A., Larrañaga E., Moreno-Otero R., Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity, J Hepatol, 2000, 33(5):716-724.
12. Jimba S., Nakagami T., Takahashi M., Wakamatsu T., Hirota Y., Iwamoto Y., Wasada T., Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults, Diabet Med, 2005, 22(9):1141-1145.
13. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., Natale S., Vanni E., Villanova N., Melchionda N., Rizzetto M., Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome, Hepatology, 2003, 37(4):917-923.
14. Avogaro P., Crepaldi G., Enzi G., Tiengo A., Associazione di iperlipemia, diabete mellito e obesità di medio grado, Acta Diabetol Lat, 1967, 4(4):572-590.
15. Reaven G. M., Banting Lecture 1988. Role of insulin resistance in human disease, Diabetes, 1988, 37(12):1595-1607.
16. Alberti K. G., Zimmet P. Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation, Diabet Med, 1998, 15(7):539-553.
17. Alberti K. G., Zimmet P. Z., World Health Organization: definition, diagnosis, and classification of diabetes mellitus and its complications, Report of a WHO consultation, Geneva, 1999.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 2001, 285(19):2486-2497.
19. Einhorn D., Reaven G. M., Cobin R. H., Ford E., Ganda O. P., Handelsman Y., Hellman R., Jellinger P. S., Kendall D., Krauss R. M., Neufeld N. D., Petak S. M., Rodbard H. W., Seibel J. A., Smith D. A., Wilson P. W., American College of Endocrinology position statement on the insulin resistance syndrome, Endocr Pract, 2003, 9(3):237-252.
20. Alberti K. G., Zimmet P., Shaw J.; IDF Epidemiology Task Force Consensus Group, The metabolic syndrome-a new worldwide definition, Lancet, 2005, 366(9491):1059-1062.
21. Grundy S. M., Cleeman J. I., Daniels S. R., Donato K. A., Eckel R. H., Franklin B. A., Gordon D. J., Krauss R. M., Savage P. J., Smith S. C. Jr., Spertus J. A., Costa F.; American Heart Association; National Heart, Lung, and Blood Institute, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 2005, 112(17):2735-2752; e285-e290.
22. Day C. P., James O. F., Steatohepatitis: a tale of two "hits"?, Gastroenterology, 1998, 114(4):842-845.
23. Bugianesi E., McCullough A. J., Marchesini G., Insulin resistance: a metabolic pathway to chronic liver disease, Hepatology, 2005, 42(5): 987-1000.
24. Sanyal A. J., Campbell-Sargent C., Mirshahi F., Rizzo W. B., Contos M. J., Sterling R. K., Luketic V. A., Shiffman M. L., Clore J. N., Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities, Gastroenterology, 2001, 120(5):1183-1192.
25. Choudhury J., Sanyal A. J., Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease, Clin Liver Dis, 2004, 8(3):575-594.
26. Samuel V. T., Liu Z. X., Qu X., Elder B. D., Bilz S., Befroy D., Romanelli A. J., Shulman G. I, Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease, J Biol Chem, 2004, 279(31):32345-32353.
27. Browning J. D., Horton J. D., Molecular mediators of hepatic steatosis and liver injury, J Clin Invest, 2004, 114(2):147-152.
28. Day C. P., Pathogenesis of steatohepatitis, Best Pract Res Clin Gastroenterol, 2002, 16(5):663-678.
29. Seki S., Kitada T., Yamada T., Sakaguchi H., Nakatani K., Wakasa K., In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases, J Hepatol, 2002, 37(1):56-62.
30. Pessayre D., Mansouri A., Fromenty B., Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis, Am J Physiol Gastrointest Liver Physiol, 2002, 282(2):G193-199.
31. Robertson G., Leclercq I., Farrell G. C., Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress, Am J Physiol Gastrointest Liver Physiol, 2001, 28(5):G1135-1139.
32. Fromenty B., Robin M. A., Igoudjil A., Mansouri A., Pessayre D., The ins and outs of mitochondrial dysfunction in NASH, Diabetes Metab, 2004, 30(2):121-138.
33. Albano E., Mottaran E., Vidali M., Reale E., Saksena S., Occhino G., Burt A. D., Day C. P., Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis, Gut, 2005, 54(7):987-993.
34. Cook K. S., Min H. Y., Johnson D., Chaplinsky R. J., Flier J. S., Hunt C. R., Spiegelman B. M., Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve, Science, 1987, 237(4813):402-405.
35. Ahima R. S., Flier J. S., Adipose tissue as an endocrine organ, Trends Endocrinol Metab, 2000, 11(8):327-332.
36. Ronti T., Lupattelli G., Mannarino E., The endocrine function of adipose tissue: an update, Clin Endocrinol (Oxf), 2006, 64(4):355-365.
37. Fain J. N., Madan A. K., Hiler M. L., Cheema P., Bahouth S. W., Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans, Endocrinology, 2004, 145(5):2273-2282.
38. Bouloumié A., Curat C. A., Sengenès C., Lolmède K., Miranville A., Busse R., Role of macrophage tissue infiltration in metabolic diseases, Curr Opin Clin Nutr Metab Care, 2005, 8(4):347-354.
39. Xu H., Uysal K. T., Becherer J. D., Arner P., Hotamisligil G. S., Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity, Diabetes, 2002, 51(6):1876-1883.
40. Weisberg S. P., McCann D., Desai M., Rosenbaum M., Leibel R. L., Ferrante A. W. Jr., Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest, 2003, 112(12):1796-1808.
41. Scherer P. E., Williams S., Fogliano M., Baldini G., Lodish H. F., A novel serum protein similar to C1q, produced exclusively in adipocytes, J Biol Chem, 1995, 270(45):26746-26749.
42. Berg A. H., Combs T. P., Scherer P. E., ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism, Trends Endocrinol Metab, 2002, 13(2):84-89.
43. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B. B., Kadowaki T., Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, Nature Medicine, 2002, 8(11):1288-1295.
44. Havel P. J., Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism, Diabetes, 2004, 53(Suppl 1):S143-151.
45. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R. E., Tataranni P. A., Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia, J Clin Endocrinol Metab, 2001, 86(5):1930-1935.
46. Hui J. M., Hodge A., Farrell G. C., Kench J. G., Kriketos A., George J., Beyond insulin resistance in NASH: TNF-alpha or adiponectin?, Hepatology, 2004, 40(1):46-54.
47. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N. H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., Kadowaki T., Cloning of adiponectin receptors that mediate antidiabetic metabolic effects, Nature, 2003, 423(6941):762-769.
48. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., Cooper G.J., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, J Clin Invest, 2003, 112(1):91-100.
49. Méndez-Sánchez N., Chavez-Tapia N. C., ZamoraValdés D., Uribe M., Adiponectin, structure, function and pathophysiological implications in non-alcoholic fatty liver disease, Mini Rev Med Chem, 2006, 6(6):651-656.
50. Méndez-Sánchez N., Chavez-Tapia N. C., Villa A. R., Sánchez-Lara K., Zamora-Valdés D., Ramos M. H., Uribe M., Adiponectin as a protective factor in hepatic steatosis, World J Gastroenterol, 2005, 11(12):1737-1741.
51. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., TsuboyamaKasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M. L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., Kadowaki T., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity, Nat Med, 2001, 7(8):941-946.
52. Stefan N., Stumvoll M., Adiponectin-its role in metabolism and beyond, Horm Metab Res, 2002, 34(9):469-474.
53. Berg A. H., Combs T. P., Du X., Brownlee M., Scherer P. E., The adipocyte-secreted protein Acrp30 enhances hepatic insulin action, Nat Med, 2001, 7(8):947-953.
54. Masaki T., Chiba S., Tatsukawa H., Yasuda T., Noguchi H., Seike M., Yoshimatsu H., Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice, Hepatology, 2004, 40(1):177-184.
55. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y., Adiponectin, an adipocytederived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway, Circulation, 2000, 102(11):1296-1301.
56. Wolf A. M., Wolf D., Rumpold H., Enrich B., Tilg H., Adiponectin induces the antiinflammatory cytokines IL-10 and IL-1RA in human leukocytes, Biochem Biophys Res Commun, 2004, 323(2):630-635.
57. Kamada Y., Tamura S., Kiso S., Matsumoto H., Saji Y., Yoshida Y., Fukui K., Maeda N., Nishizawa H., Nagaretani H., Okamoto Y., Kihara S., Miyagawa J., Shinomura Y., Funahashi T., Matsuzawa Y., Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin, Gastroenterology, 2003, 125(6):1796-1807.
58. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., Ebenbichler C. F., Patsch J. R., Tilg H., Adiponectin and its receptors in non-alcoholic steatohepatitis, Gut, 2005, 54(1):117-121.
59. Tilg H., Diehl A. M., Cytokines in alcoholic and nonalcoholic steatohepatitis, N Engl J Med, 2000, 343(20):1467-1476.
60. Shapiro L., Scherer P. E., The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor, Curr Biol, 1998, 8(6):335-338.
61. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., Furuyama N., Kondo H., Takahashi M., Arita Y., Komuro R., Ouchi N., Kihara S., Tochino Y., Okutomi K., Horie M., Takeda S., Aoyama T., Funahashi T., Matsuzawa Y., Diet-induced insulin resistance in mice lacking adiponectin/ACRP30, Nat Med, 2002, 8(7):731-737.
62. Feinstein R., Kanety H., Papa M. Z., Lunenfeld B., Karasik A., Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates, J. Biol Chem, 1993, 268(35):26055-26058.
63. Hotamisligil G. S., Shargill N. S., Spiegelman B. M., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance, Science, 1993, 259(5091):87-91.
64. Crespo J., Cayón A., Fernández-Gil P., HernándezGuerra M., Mayorga M., Domínguez-Díez A., FernándezEscalante J. C., Pons-Romero F., Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients, Hepatology, 2001, 34(6):1158-1163.
65. Valenti L., Fracanzani A. L., Dongiovanni P., Santorelli G., Branchi A., Taioli E., Fiorelli G., Fargion S., Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease, Gastroenterology, 2002, 122(2):274-280.
66. Cai D., Yuan M., Frantz D. F., Melendez P. A., Hansen L., Lee J., Shoelson S. E., Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB, Nat Med, 2005, 11(2):183-190.
67. Choi S., Diehl A. M., Role of inflammation in nonalcoholic steatohepatitis, Curr Opin Gastroenterol, 2005, 21(6):702-707.
68. Uygun A., Kadayifci A., Yesilova Z., Erdil A., Yaman H., Saka M., Deveci M. S., Bagci S., Gulsen M., Karaeren N., Dagalp K., Serum leptin levels in patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 2000, 95(12):3584-3589.
69. Leclercq I. A., Farrell G. C., Schriemer R., Robertson G. R., Leptin is essential for the hepatic fibrogenic response to chronic liver injury, J Hepatol, 2002, 37(2):206-213.
70. Day C. P., The potential role of genes in nonalcoholic fatty liver disease, Clin Liver Dis, 2004, 8(3):673-691.
71. Merriman R. B., Aouizerat B. E, Bass N. M., Genetic influences in nonalcoholic fatty liver disease, J Clin Gastroenterol, 2006, 40(3 Suppl 1):S30-33.
72. Day C. P., Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease, Liver Int, 2006, 26(9):1021-1028.
73. Di Marzo V., Matias I., Endocannabinoid control of food intake and energy balance, Nat Neurosci, 2005, 8(5):585-589.
74. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Bátkai S., Harvey-White J., Mackie K., Offertáler L., Wang L., Kunos G., Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity, J Clin Invest, 2005, 115(5):1298-1305.
75. Zamora-Valdés D., Ponciano-Rodríguez G., ChávezTapia N. C., Méndez-Sánchez N., The endocannabinoid system in chronic liver disease, Ann Hepatol, 2005, 4(4):248-254.
76. Chitturi S., Farrell G. C., Hashimoto E., Saibara T., Lau G. K., Sollano J. D.; Asia-Pacific Working Party on NAFLD, Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines, J Gastroenterol Hepatol, 2007, 22(6):778-787.
77. Chan H. L., de Silva H. J., Leung N. W., Lim S. G., Farrell G. C.; Asia-Pacific Working Party on NAFLD, How should we manage patients with non-alcoholic fatty liver disease in 2007?, J Gastroenterol Hepatol, 2007, 22(6):801-808.
78. McCullough A. J., Update on nonalcoholic fatty liver disease, J Clin Gastroenterol, 2002, 34(3):255-262.
79. Fan J. G., Saibara T., Chitturi S., Kim B. I., Sung J. J., Chutaputti A.; Asia-Pacific Working Party for NAFLD, What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?, J Gastroenterol Hepatol, 2007, 22(6):794-800.
80. Saadeh S., Younossi Z. M., Remer E. M., Gramlich T., Ong J. P., Hurley M., Mullen K. D., Cooper J. N., Sheridan M. J., The utility of radiological imaging in nonalcoholic fatty liver disease, Gastroenterology, 2002, 123(3):745-750.
81. Cadranel J. F., Rufat P., Degos F., Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF), Hepatology, 2000, 32(3):477-481.
82. Poynard T., Ratziu V., Bedossa P., Appropriateness of liver biopsy, Can J Gastroenterol, 2000, 14(6):543-548.
83. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., Grimaldi A., Capron F., Poynard T.; LIDO Study Group, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 2005, 128(7):1898-1906.
84. Hübscher S. G., Role of liver biopsy in the assessment of non-alcoholic fatty liver disease, Eur J Gastroenterol Hepatol, 2004, 16(11):1107-1115.
85. Kleiner D. E., Brunt E. M., Van Natta M., Behling C., Contos M. J., Cummings O. W., Ferrell L. D., Liu Y. C., Torbenson M. S., Unalp-Arida A., Yeh M., McCullough A. J., Sanyal A. J.; Nonalcoholic Steatohepatitis Clinical Research Network, Design and validation of a histologic scoring system for nonalcoholic fatty liver disease, Hepatology, 2005, 41(6):1313-1321.
86. Angulo P., Keach J. C., Batts K. P., Lindor K. D., Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis, Hepatology, 1999, 30(6):1356-1362.
87. Sasaki N., Ueno T., Morita Y., Nagata E., Sata M., Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH), Hepatogastroenterology, 2006, 53(71):678-681.
88. Guha I. N., Parkes J., Roderick P. R., Harris S., Rosenberg W. M., Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease, Gut, 2006, 55(11):1650-1660.
89. Nugent C., Younossi Z. M., Evaluation and management of obesity-related nonalcoholic fatty liver disease, Nat Clin Pract Gastroenterol Hepatol, 2007, 4(8):432-441.
90. Tilg H., Kaser A., Treatment strategies in nonalcoholic fatty liver disease, Nat Clin Pract Gastroenterol Hepatol, 2005, 2(3):148-155.